First-line (1L) osimertinib plus platinum-pemetrexed in EGFRmutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results

被引：0
|
作者：
Planchard, D. [1 ]
Poltoratskiy, A. [2 ]
Kim, S-W. [3 ]
Kim, T. M. [4 ]
Yanagitani, N. [5 ]
Kagamu, H. [6 ]
Feng, P-H. [7 ]
Hughes, B. [8 ]
Yang, T-Y. [9 ]
Yang, J. C-H. [10 ,11 ]
Lee, C. K. [12 ]
Karaseva, N. [13 ]
Mitchell, P. [14 ]
Tambo, Y. [15 ]
Monterroso, E. Armenteros [16 ]
Todd, A. [17 ]
Sahasrabudhe, A. [18 ]
Janne, P. A. [19 ]
Kobayashi, K. [20 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France
[2] Petrov Res Inst Oncol, Dept Preclin & Clin Trials, St Petersburg, Russia
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan
[6] Saitama Med Univ, Dept Gen Surg, Saitama, Japan
[7] Taipei Med Univ, Shuang Ho Hosp, Div Pulm Med, Dept Internal Med, Taipei, Taiwan
[8] Prince Charles Hosp, Dept Canc Care Serv, Herston, Qld, Australia
[9] Taichung Vet Gen Hosp, Dept Pulm Med, Taichung, Taiwan
[10] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[12] St George Hosp, Dept Med Oncol, Canc Care Ctr, Kogarah, NSW, Australia
[13] City Clin Oncol Hosp, Thorac Dept, St Petersburg, Russia
[14] Austin Hlth, Olivia Newton John Canc Ctr, Dept Oncol, Melbourne, Vic, Australia
[15] Kanazawa Univ Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan
[16] AstraZeneca, Late Dev Oncol R&D, Cambridge, England
[17] AstraZeneca, Oncol Biometr, Cambridge, England
[18] AstraZeneca, Dept Patient Safety Oncol, Cambridge, England
[19] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Dept Med Oncol, Boston, MA 02115 USA
[20] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.646
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
568P
引用
收藏
页码：S1692 / S1693
页数：2
相关论文
共 50 条
  • [41] RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.
    Spigel, David R.
    Paz-Ares, Luis G.
    Chen, Yuanbin
    Jove, Maria
    Juan-Vidal, Oscar
    Rich, Patricia
    Hayes, Theresa M.
    Calderon, M. Vanesa Gutierrez
    Caro, Reyes Bernabe
    Navarro, Alejandro
    Dowlati, Afshin
    Zhang, Bin
    Moore, Yan
    Wang, Haofei Tiffany
    Kokhreidze, Jaba
    Nazarenko, Natalya
    Aix, Santiago Ponce
    Bunn, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line (1L) Treatment (tx) of Advanced Nsclc: Overall Survival (Os) Analysis of Checkmate 817
    Fischer, Juergen R.
    Barlesi, Fabrice
    Audigier-Valette, Larisse
    Felip, Enriqueta
    Ciuleanu, Tudor-Eliade
    Jao, Kevin
    Rijavec, Erika
    Urban, Laszlo
    Aucoin, Jean-Sebastien
    Zannori, Cristina
    Vermaelen, Karim
    Aren Frontera, Osvaldo
    Ready, Neal
    Fontecedro, Alessandra Curioni
    Linardou, Helena
    Poddubskaya, Elena
    Pillai, Rathi
    Li, Sunney
    Acevedo, Angelic
    Paz-Ares, Luis
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
  • [43] Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts
    Yang, J. C-H.
    Ramalingam, S. S.
    Lee, C. K.
    Kurata, T.
    Kim, D-W.
    John, T.
    Nogami, N.
    Ohe, Y.
    Rukazenkov, Y.
    Murphy, M.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Real-world effectiveness and safety of fi rst-line (1L) osimertinib for EGFR-mutated (EGFRm) advanced NSCLC: A prospective, multi-center, real-world study in China (FLOURISH Study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1653 - S1654
  • [45] Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.
    Goldman, Jonathan Wade
    Antonia, Scott Joseph
    Gettinger, Scott N.
    Borghaei, Hossein
    Brahmer, Julie R.
    Ready, Neal E.
    Gerber, David E.
    Chow, Laura Q.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott Andrew
    Geese, William J.
    Li, Ang
    Li, Xuemei
    Hellmann, Matthew David
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Mechanisms of acquired resistance to fi rst-line (1L) osimertinib in EGFR-mutated (EGFRm) advanced NSCLC: Results from a prospective, multi-center, real-world study in China (FLOURISH study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1663 - S1663
  • [47] Zanidatamab plus chemotherapy for first-line (1L) treatment of HER2+advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial
    Elimova, E.
    Ajani, J. A.
    Burris, H. A.
    Denlinger, C. S.
    Iqbal, S.
    Kang, Y-K.
    Kim, J. H.
    Lee, K-W.
    Lin, B.
    Mehta, R.
    Oh, D-Y.
    Rha, S. Y.
    Seol, Y. M.
    Xie, C.
    Garfin, P.
    Ku, G. Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S887 - S888
  • [48] Pelareorep (pela) plus atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
    Arnold, D.
    Goekkurt, E.
    Stein, A.
    Martens, U. M.
    Chater, J.
    Ungerechts, G.
    Loghmani, H.
    Coffey, M.
    Trauger, R.
    Heineman, T. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S899 - S899
  • [49] Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
    Borghaei, H.
    Langer, C. J.
    Gadgeel, S.
    Papadimitrakopoulou, V. A.
    Patnaik, A.
    Powell, S. F.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Jalal, S. I.
    Panwalkar, A.
    Yang, J. C-H.
    Gubens, M.
    Sequist, L.
    Awad, M. M.
    Fiore, J.
    Saraf, S.
    Raftopoulos, H.
    Gandhi, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
    Yang, Yunpeng
    Wang, Zhehai
    Fang, Jian
    Yu, Qitao
    Han, Baohui
    Cang, Shundong
    Chen, Gongyan
    Mei, Xiaodong
    Yang, Zhixiong
    Ma, Rui
    Bi, Minghong
    Ren, Xiubao
    Zhou, Jianying
    Li, Baolan
    Song, Yong
    Feng, Jifeng
    Li, Juan
    He, Zhiyong
    Zhou, Rui
    Li, Weimin
    Lu, You
    Wang, Yingyi
    Wang, Lijun
    Yang, Nong
    Zhang, Yan
    Yu, Zhuang
    Zhao, Yanqiu
    Xie, Conghua
    Cheng, Ying
    Zhou, Hui
    Wang, Shuyan
    Zhu, Donglei
    Zhang, Wen
    Zhang, Li
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : 1636 - 1646
12345